Asembia Specialty Pharmacy Summit

Biosimilars are also expanding rapidly, offering new opportunities for payers, patients, and providers.

Panelists at AXS23 conference agree that the patient’s voice is the most critical, whether it is related to drug manufacturing, delivery, or marketing.

Pharmacists will play a growing role in the use of biosimilars and guiding patients through the switching process.

Although these programs are not the entire solution to rising pharmacy costs, Marsh said they are an important part of solving the problem.

The COVID-19 pandemic revealed some of the major gaps in trust in the United States, but Johnson said pharmacists are key to improving it.

The law directs federal spending toward funding the internal revenue service, improving taxpayer compliance, lowering health care needs, and reducing carbon emissions.

Naveen Mansukhani, BPharm, discussed skyrocketing prices for specialty drugs and what is driving those increases.

Fran Gregory, PharmD, MBA, vice president of Emerging Therapies at Cardinal Health, discussed the biosimilars landscape and where biosimilars fall in the process of pharmacy and medical benefit adoption.

Balancing clinicians’ priorities with the needs of patients and their families is crucial to ensure access and adherence to medications.

Pharmacists play key roles in navigating prior authorizations and other limits on utilization, as well as educating and listening to patients and caregivers.

Session at the 2023 Asembia Summit notes that pharmacists play a particularly important role in the large multidisciplinary care team needed for Rett syndrome management.

Cate Lockhart, PharmD, PhD, executive director of the Biologics and Biosimilars Collective Intelligence Consortium, discussed the growing biosimilars landscape .

Annual Asembia summit features insights from key opinion leaders, networking events, and continuing education sessions for pharmacists, pharmacy staff and stakeholders.

Neil Lund, senior advisor, Avelere Health and Ryan Urgo, managing director, Health Policy, Avelere Health, discuss the impact of President Biden’s health care agenda on the pharmacy field.

Doug Long, vice president, Industry Relations, IQVIA, discusses notable trends reshaping specialty pharmaceutical channels and the impact of these developments on the role of the pharmacist in the health care team.

Ray Tancredi, divisional vice president of Specialty Pharmacy, Development & Brand Rx/Vaccine Purchasing at Walgreens, discusses blockbuster drugs in the oncology space that have been approved this year or may be hitting the market soon.

Tracy Russell, senior director, State Government Affairs at CoverMyMeds, discusses state and federal legislation that may be impacting the future of specialty pharmacies and the patient care they deliver.

Sneha Sharma, director, specialty clinical solutions at Magellan Health, discusses some trends in the rare disease space that she recommends pharmacists keep an eye on this year.

Amy Ware, director, specialty clinical solutions at Magellan Health, discusses what it means to be future focused as a pharmacist in the specialty pharmacy field.

Jayne Hornung, chief clinical officer – pharmacy, Managed Markets Insight & Technology, discusses her presentation on potential causes of the slow uptake in digital therapeutics among payers.

Tracy Russell, senior director, State Government Affairs at CoverMyMeds, discusses her presentation at Asembia Summit 2022 on legislation aligned with the movement to expand the pharmacist’s role on the care team.

Regardless of the ability to access and dispense products, pharmacists are responsible for getting patients the best care.

Pharmacists can play a more active role in educating patients on tools and resources available to them, enrolling patients in programs, gathering subjective and objective data.

Ray Tancredi, divisional vice president of Specialty Pharmacy, Development & Brand Rx/Vaccine Purchasing at Walgreens, addresses his presentation on the specialty pharmaceutical pipeline, and specifically what approvals pharmacists should look for on the horizon.

Sonia T. Oskouei, PharmD, vice president of biosimilars at Cardinal Health, discussed how pharmacists can impact biosimilar adoption.

Jayson Slotnik, JD, MPH, partner at Health Policy Strategies, discusses his hopes for the future of value-based contracting and the ideal model for pharmacy’s involvement.

Patient data are essential to providing coordinator care, but more data also creates heightened risks.

Prescription medications are vital to optimal patient outcomes, but they are also becoming increasingly expensive.

Ray Tancredi, divisional vice president of Specialty Pharmacy, Development & Brand Rx/Vaccine Purchasing at Walgreens, discusses some of the more significant drugs for specialty pharmacy in the FDA pipeline this year.

Digital medicine is the use of technology to measure or intervene in certain health conditions and is overseen by the FDA, unlike digital health apps or technologies.